GlassScriptPhysician profile
Blaise E Ferraraccio
NPI 1679539142
$4,631.91
in general payments reported to CMS, 2019-2025
34 companies · $78.72 in 2025
The $78.72 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $1,371 · 2021: $32.92 · 2022: $882 · 2023: $1,137 · 2024: $20.70 · 2025: $78.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.69 |
| Education | $170.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $639.81 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $602.96 | 2019-2023 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $463.78 | 2019-2020 | |
| Abbvie INC. | $463.31 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $383.66 | 2022-2023 | Ingrezza, Ongentys |
| Emd Serono, INC. | $378.87 | 2019-2020 | |
| Lilly USA, LLC | $285.78 | 2019-2023 | Amyvid |
| Biohaven Pharmaceutical Holding Company LTD. | $228.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $150.11 | 2019-2023 | |
| Pfizer INC. | $129.68 | 2023 | |
| Sk Life Science, INC. | $105.65 | 2020-2023 | |
| Lundbeck LLC | $104.90 | 2019-2023 | Vyepti |
| Ucb, INC. | $64.55 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $63.79 | 2020 | |
| Acadia Pharmaceuticals INC | $59.53 | 2022-2023 | Nuplazid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $58.55 | 2025 | Hizentra |
| Genentech USA, INC. | $57.58 | 2023 | Ocrevus, Enspryng |
| Amneal Pharmaceuticals LLC | $56.16 | 2019-2023 | Rytary |
| Amgen INC. | $54.15 | 2019-2023 | Repatha, Otezla |
| Avanir Pharmaceuticals, INC. | $48.09 | 2020-2022 | |
| Greenwich Biosciences, INC. | $34.21 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $25.83 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $20.17 | 2025 | Verquvo |
| Alexion Pharmaceuticals, INC. | $19.06 | 2023 | Ultomiris |
| Biogen, INC. | $16.52 | 2020 | |
| Kyowa Kirin, INC. | $16.51 | 2020 | |
| Eisai INC. | $16.15 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.09 | 2023 | Rexulti |
| Arbor Pharmaceuticals, INC. | $13.27 | 2020 | |
| Argenx US, INC. | $13.17 | 2024 | Vyvgart Hytrulo |
| Allergan, INC. | $12.50 | 2019 | |
| Currax Pharmaceuticals LLC | $11.67 | 2020 | |
| Livanova USA, INC. | $11.25 | 2019 | |
| Insightec,INC | $7.53 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blaise Ferraraccio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.